Vericel VCEL
NASDAQ VCEL
$38.99 -0.09 (-0.23%)
As of: Sep 9, 2026 · 3:59 PM EDT

Vericel (VCEL) Long-Term Debt Issuances (2013 - 2017)

Vericel's (VCEL) quarterly Long-Term Debt Issuances came in at $14.8 million in Q4 2017, up 243.23% year-over-year from $4.3 million in Q4 2016, and up 74065.0% quarter-over-quarter from -$20000.0 in Q3 2017.

Analysis

Vericel (VCEL) Long-Term Debt Issuances (2013 - 2017) Analysis & Trends

Vericel has disclosed Long-Term Debt Issuances across 5 years of filings, most recently posting $14.8 million for Q4 2017.

  • In Q4 2017, Long-Term Debt Issuances rose 243.23% year-over-year to $14.8 million; the TTM figure through Dec 2017 stood at $14.8 million (up 16.39% YoY), while the FY2018 annual figure was $17.5 million, up 18.52% from the prior year.
  • Long-Term Debt Issuances came in at $14.8 million for Q4 2017 at Vericel, up from -$20000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $14.8 million in Q4 2017 to a low of -$20000.0 in Q3 2017.
  • Average Long-Term Debt Issuances over 5 years is $2.0 million, with a median of $9000.0 recorded in 2015.
  • Year-over-year, Long-Term Debt Issuances jumped 66566.67% in 2016 and plunged 100.33% in 2017.
  • Over 5 years, Long-Term Debt Issuances stood at $4000.0 in 2013, then surged by 62300.0% to $2.5 million in 2014, then slumped by 99.64% to $9000.0 in 2015, then jumped by 47788.89% to $4.3 million in 2016, then soared by 243.23% to $14.8 million in 2017.
  • Per Business Quant data, the three most recent Long-Term Debt Issuances figures were $14.8 million in Q4 2017, -$20000.0 in Q3 2017, and $10000.0 in Q2 2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn -
2 CRISPR Therapeutics AG 5.17 Bn 5.17 Bn - -
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn -
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn -
5 uniQure 3.05 Bn 3.05 Bn 5.49 Mn -
6 Beam Therapeutics 2.65 Bn 2.65 Bn - -
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn -
8 Sarepta Therapeutics 2.33 Bn 1.53 Bn 251.87 Mn -
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn -
10 Taysha Gene Therapies 1.97 Bn 1.97 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 14.79 Mn
Sep 30, 2017 -20,000.00
Jun 30, 2017 10,000.00
Mar 31, 2017 10,000.00
Dec 31, 2016 4.31 Mn
Sep 30, 2016 6.00 Mn
Jun 30, 2016 2.39 Mn
Mar 31, 2016 9,000.00
Dec 31, 2015 9,000.00
Sep 30, 2015 9,000.00
Jun 30, 2015 8,000.00
Mar 31, 2015 9,000.00
Jun 30, 2014 2.50 Mn
Mar 31, 2014 4,000.00
Dec 31, 2013 4,000.00